No Detail Found!

Assessing the schematic molecular insights to therapeutic potential of Brain- Derived Neurotrophic Factor in treating and managing glaucoma

Author(s)
Saeed Ahmad Department of Biotechnology and Microbiology, Bacha Khan University, Pakistan
Muhammad Usman Durrani Departments of Ophthalmology, PNS Shifa Karachi, Pakistan
Abdul Munim Peshawar Medical College, Pakistan
Asim Mehmood Department of Anatomy, Suleman Roshan Medical College, Pakistan
Muhammad Imran Ali Department of Ophthalmology, King Khalid Hospital, Al-Majmaah, Pakistan
Madeeha Minhas Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University, Jeddah, KSA
Abstract
Objective: To investigate the neuro-ophthalmic interface through Brain-Derived Neurotrophic Factor (BDNF) molecular activity and its therapeutic value in glaucoma treatment. Methodology: The role of BDNF in neuroprotection for glaucoma was evaluated through studies published between 2010 and 2024, following the PRISMA 2020 methodology. The search included PubMed, Scopus, and other relevant databases using keywords related to glaucoma, BDNF, neuroprotection, and therapeutic interventions. A total of 45 studies were reviewed, and 10 studies met the criteria for further investigation. These studies focused on BDNF molecular pathways and their effect on retinal ganglion cell survival, along with corresponding BDNF-based clinical therapies. The evaluation of risk bias used the Cochrane Risk of Bias Tool and GRADE criteria to make assessments about evidence quality. Results: We found that BDNF is a vital factor in sustaining retinal ganglion cells and regulating intraocular pressure, both of which are important for glaucoma pathology. Basic Fibroblast Growth Factor-based treat-ment methods showed promising results by protecting retinal ganglion cells from damage and improving cell-ular function in laboratory models. BDNF administrat-ion through advanced drug delivery techniques could help glaucoma patients maintain good vision while min-imally advancing disease progression. Multiple therape-utic agents combined with BDNF produced beneficial effects that surpassed individual treatment results. Conclusion: BDNF functions as a promising Molecu-lar target for glaucoma treatment, offering new opportu-nities to protect optic nerves together with disease mod-ifications. Scientists should concentrate their research on developing ideal delivery systems and investigating the long-term effectiveness of BDNF-based treatments in clinical practice.
Publication Details
Page(s) 789-793
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
glaucoma, BDNF, Neuroprotection, molecular therapy, Neurotrophic factors, intraocular pressure., retinal ganglion cells
References
Wagner IV,Stewart MW,Dorairaj SK .2022 .Updates on the Diagnosis and Management of Glaucoma. Mayo Clin Proc Innov Qual Outcomes, 6 : 618-35.
Hopf S,Schwantuschke D,Schmidtmann I,Pfeiffer N,Hoffmann EM .2021 .Impact of intraocular pressure fluctuations on progression of normal tension glaucoma. Int J Ophthalmol, 14 : 1553-9.
Leung DYL,Tham CC .2022 .Normal-tension glaucoma: Current concepts and approaches-A review. Clin Exp Ophthalmol, 50 : 247-59.
Lu YC,Pu C,Hou CH .2021 .The Effect of Continuity of Care and Provider Volume on Late Presentation of Glaucoma: A Nested Case-Control Study. J Glaucoma, 30 : 187-91.
Kasahara M,Shoji N. .2021 .Effectiveness and limitations of minimally invasive glaucoma surgery targeting Schlemm's canal. Jpn J Ophthalmol, 65 : 6-22.
Mincione F,Nocentini A,Supuran CT .2021 .Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov, 16 : 1209-25.
Wang LH,Huang CH,Lin IC .2024 .Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies. Pharmaceuticals, 17 : 1261-7.
Fudalej E,Justyniarska M,Kasarełło K,Dziedziak J,Szaflik JP,Cudnoch-Jędrzejewska A .2021 .Neuroprotective Factors of the Retina and Their Role in Promoting Survival of Retinal Ganglion Cells: A Review. Ophthalmic Res, 64 : 345-55.
Wang X,Sun L,Han X,Li Z,Xing Y,Chen X .2025 .The molecular mechanisms underlying retinal ganglion cell apoptosis and optic nerve regeneration in glaucoma (Review). Int J Mol Med, 55 : 63-8.
Yuan Y,Lin TPH,Gao K,Zhou R,Radke NV,Lam DSC .2021 .Aerobic exercise reduces intraocular pressure and expands Schlemm's canal dimensions in healthy and primary open-angle glaucoma eyes. Indian J Ophthalmol, 69 : 1127-34.
Taniguchi T,Sharif NA,Ota T,Farjo RA,Rausch R .2024 .Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush. Pharmaceuticals, 17 : 798-802.
Sato K,Takada N,Fujioka A,Himori N,Yokoyama Y,Tsuda S .2023 .Reduced Plasma BDNF Levels in Normal Tension Glaucoma Compared to Open Angle Glaucoma. J Glaucoma, 32 : 734-7.
Cha YW,Kim ST .2021 .Serum and aqueous humor levels of brain-derived neurotrophic factor in patients with primary open-angle glaucoma and normal-tension glaucoma. Int Ophthalmol, 41 : 3869-75.
Park HL,Kim SW,Kim JH,Park CK .2019 .Increased levels of synaptic proteins involved in synaptic plasticity after chronic intraocular pressure elevation and modulation by brain-derived neurotrophic factor in a glaucoma animal model. Dis Model Mech, 12 : 1-12.
Oddone F,Roberti G,Micera A,Busanello A,Bonini S,Quaranta L .2017 .Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages. PLoS One, 12 : e0168565.
Domenici L,Origlia N,Falsini B,Cerri E,Barloscio D,Fabiani C .2014 .Rescue of retinal function by BDNF in a mouse model of glaucoma. PLoS One, 9 : e115579.
Ghaffariyeh A,Honarpisheh N,Heidari MH,Puyan S .2011 .Brain-derived neurotrophic factor as a biomarker in primary open-angle glaucoma. Optom Vis Sci, 88 : 80-5.
Igarashi T,Nakamoto K,Kobayashi M,Suzuki H,Tobita Y,Igarashi T .2021 .Serum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study. J Nippon Med Sch, 87 : 339-45.
Harper MM,Boese EA,Kardon RH,Ledolter J,Kuehn MH .2021 .High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina. Curr Eye Res, 46 : 739-45.
Yarube I,Saidu A,Hassan S. .2019 .Intraocular pressure negatively correlates with serum brain-derived neurotrophic factor in patients with primary open-angle glaucoma. SubSaharan Afr J Med, 6 : 10-13.
Skopiński P,Radomska-Leśniewska DM,Izdebska J,Kamińska A,Kupis M,Kubiak AJ .2021 .New perspectives of immunomodulation and neuroprotection in glaucoma. Cent Eur J Immunol, 46 : 105-110.
Agarwal R,Agarwal P,Iezhitsa I. Exploring .2023 .the current use of animal models in glaucoma drug discovery: where are we in 2023? Expert Opin Drug Discov. , 18 : 1287-1300.
Ho K,Bodi NE,Sharma TP .2024 .Normal-Tension Glaucoma and Potential Clinical Links to Alzheimer's Disease. J Clin Med, 13 : 1948-53.
Kumar A,Ou Y. .2023 .From bench to behavior: The role of lifestyle factors on intraocular pressure, neuroprotection, and disease progression in glaucoma. Clin Exp Ophthalmol, 51 : 380-94.
0

Citations

0

Downloads

90

Views